Glycemic Outcomes During Early Use of the MiniMed™ 780G Advanced Hybrid Closed-Loop System with Guardian™ 4 Sensor
Authors' conclusion
Early clinical use of the MM780G+G4S was safe and involved minimal BGMs and AHCL exits. Consistent with real-world pediatric and adult use, outcomes were associated with achievement of recommended glycemic targets.
Study context
- Population
- Continued access study (CAS) participants who transitioned from the pivotal advanced hybrid closed-loop (AHCL) trial system to MiniMed 780G with calibration-free Guardian 4 Sensor; real-world users with ≥10 days continuous glucose monitoring (CGM) data (Sept 22, 2021 to Dec 02, 2022)
- Participants
- 109 / 67 / 10,204 / 26,099
- Exposure
- CAS participants vs real-world MM780G+G4S users
- CAS pediatricn = 109
- CAS adultn = 67
- Real-world pediatricn = 10,204
- Real-world adultn = 26,099
- Outcome
- Time in AHCL and CGM use
Methodological detailsdescriptive analyses
- Descriptive analyses
Main finding
As reported in the abstract
- Time in AHCL and CGM use for all groups
- >90%
- AHCL exits averaged
- 0.1/day
- Blood glucose measurements (BGMs)
- 0.8/day-1.0/day
- Use of recommended glucose target (100 mg/dL) and active insulin time (2 h) settings, CAS pediatric
- 28.4%
- Use of recommended glucose target (100 mg/dL) and active insulin time (2 h) settings, real-world pediatric
- 9.4%
Observational data: associations, not effects.
Further findings
| Outcome | CAS pediatric | CAS adult |
|---|---|---|
| A1C · 3 months | 7.2% ± 0.7% | 6.8% ± 0.7% |
Safety
- Serious adverse events in CAS
- 0
Original publication
Glycemic Outcomes During Early Use of the MiniMed™ 780G Advanced Hybrid Closed-Loop System with Guardian™ 4 Sensor. Diabetes Technol Ther. Published 16 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →